Jaguar Health 3Q 2026: Revenue $2.34M, EPS ($9.23) — 10-Q Summary

Jaguar Health reported 3Q 2026 revenue of $2.34M, down 24% YoY, with net loss narrowing to $6.31M. License revenue rose to $1.8M, while product revenue declined due to lower Mytesi sales. R&D expenses decreased slightly, and commercial costs dropped significantly after transferring Mytesi and Canalevia commercialization to Woodward. The company's pivotal pediatric MVID trial is ongoing, with clinical work continuing for crofelemer powder.

Original reporting
Published Nov 16, 2026, 11:41 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 11:55 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Jaguar Health 3Q 2026: Revenue $2.34M, EPS ($9.23) — 10-Q Summary — source image
Decision brief

The 30-second read

$JAGXBearishMed
01

Why it matters

The disclosed revenue miss and continued net loss suggest short‑term pressure, but the Woodward license payment and trial extensions could be positive catalysts.

02

Market read

Primary disclosure of quarterly financials for a micro‑cap biotech; likely moves the stock on earnings reaction.

03

What to watch

R&D spend only slightly down; potential pipeline progress in MVID trial may offer upside.

Relevance 6/10Novelty 6/10Timing: after‑hours filing

Background

Jaguar Health is a clinical‑stage biotech focused on rare pediatric diseases. The 10‑Q reports its latest quarter results.

Company-level read

Ticker impact

$JAGXBearishHigh confidence
Context

Quarterly 10‑Q filing shows revenue down 24% YoY to $2.34M and EPS loss of $9.23 per share.

Expected impact

likely downside as market prices in weaker revenue and continued losses

Evidence & confidence

The filing provides fresh, material financial metrics for a micro‑cap; investors typically react to revenue miss and large per‑share loss.

Market effects

Highlights ongoing weakness in niche biotech licensing revenue.

Limited to U.S. micro‑cap biotech investors.

Low; no broader market impact.

Counterpoint

If the Woodward holdback payment signals a longer‑term partnership, the stock could stabilize.

Key entities

  • Jaguar Health, Inc.

    Micro‑cap biotech reporting Q3 2026 results.

  • Woodward

    Licensee providing a $1.8M holdback payment.

Related articles

$JAGXMed

Jaguar Health Reports Third Quarter 2026 Financials

Jaguar Health, Inc. (JAGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Jaguar Health Reports Third Quarter 2026 Financials Jaguar’s rare disease intestinal failure development program for microvillus inclusion disease (MVID) and short bowel syndrome for crofelemer powder for oral solution is expected to continue to provide clinical mile

$JAGXMedAI 8/10

Jaguar Health, Inc.: Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure in Third Rare Congenital Enteropathy Disorder

Jaguar Health (JAGX) announced that its drug crofelemer has shown benefits in treating intestinal failure in pediatric patients with GUCY2C gene mutation, reducing parenteral support needs. The company plans to file for FDA approval for MVID in mid-2027. Crofelemer has also shown promise in reducing parenteral support needs in patients with MVID and SBS-IF.

$JAGXMedAI 8/10

Jaguar Health unit treats infant with rare intestinal disorder

Jaguar Health Inc. (JAGX) announced its subsidiary Napo Pharmaceuticals is treating an infant with congenital sodium diarrhea using crofelemer, reducing parenteral support needs by 15%. The company plans to file a New Drug Application for microvillus inclusion disease in mid-2027, with trial data showing significant reductions in parenteral support for pediatric patients.